The rapid development of chemical biology and biomedicine opens up new exciting opportunities for diagnostics, treatment and translational research on human diseases. However, it also puts high requirements to research involved with biomedical projects. Aptol Pharma aims to develop and promote novel diagnostic and therapeutic options for human autoimmune diseases. Aptol Pharma mission is to improve healthcare in the society using most recent developments in chemistry, synthetic biology and biomedicine. Currently 4 founders of the company create and implement strategic vision and decisions, founders are: Kira Astakhova - Ass. Professor at DTU, Expert in the aptamer technology development Mads Clausen - Professor at DTU and expert in bioorganic chemistry Tue Wenzel Kragstrup - Rheumatology specialist, Clinician Mark Daniel Zalomajev - marketing and business developer